title: Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
abstract: Currently no treatment has proved successful in inducing ovarian steroidogenic and/or gametogenic recovery in patients with haematological malignancies treated by cytotoxic chemotherapy once biochemical failure becomes manifest i.e., when FSH levels exceed 40 IU/L. This paper reports two such cases with classical biochemical ovarian failure in which ovarian function was induced by brief stimulation with Human Menopausal Gonadotrophin (HMG).
authors.affiliation: Department of Obstetrics and Gynaecology, University College and Middlesex School of Medicine, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Chatterjee
authors.forename: W
authors.initials: W
authors.lastname: Mills
authors.forename: M
authors.initials: M
authors.lastname: Katz
authors.forename: H H
authors.initials: HH
authors.lastname: McGarrigle
authors.forename: A H
authors.initials: AH
authors.lastname: Goldstone
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy / Q000628:therapy; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008596:Menotropins / Q000627:therapeutic use*; D010062:Ovulation Induction; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011272:Pregnancy, Multiple; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000188:drug therapy*; D012074:Remission Induction; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects; D013866:Thioguanine / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D008596:Menotropins; D004317:Doxorubicin; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013713:Teniposide; D013866:Thioguanine; D011034:Podophyllotoxin; D002945:Cisplatin; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone; D003630:Daunorubicin